1. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic;Citrome;Int J Clin Pract,2009
2. 2Vanda Pharmaceuticals. Vanda Pharmaceuticals Announces Receipt of not Approvable Letter From FDA for Iloperidone. Press release, 28 July 2008. http://phx.corporate-ir.net/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=1179851&highlight (accessed December 2009).
3. 3Novartis. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia. Press release, 12 October 2009. http://www.novartis.com/newsroom/media-releases/en/2009/1346595.shtml (accessed December 2009).
4. 4FDA. Drug Approval Package. Fanapt (Iloperidone) Tablets. 12 June 2009. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022192s000TOC.cfm (accessed December 2009).
5. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making;Volavka;Expert Opin Pharmacother,2009